Antibacterial properties and reduction of MRSA biofilm with a dressing combining polyabsorbent fibres and a silver matrix.
OBJECTIVE
This study was designed to evaluate the antibacterial activity of a wound dressing which combines polyacrylate fibres and a silver lipido-colloid matrix (UrgoClean Ag, silver polyabsorbent dressing), against biofilm of methicillin-resistant Staphylococcus aureus (MRSA).


METHODS
Samples of silver polyabsorbent dressing and the neutral form of this dressing (UrgoClean) were applied to biofilms of MRSA formed on a collagen I-coated surface, cultured for 24 hours. Different exposure times were tested (1, 2, 4 and 7 days) without dressing change. The biofilm reduction was quantified by using culture methods and by confocal laser scanning microscopy experiments.


RESULTS
The application of the silver polyabsorbent dressing resulted in a significant decrease of the biofilm population by a log reduction of 4.6, after 24 hours of exposure. Moreover, the antibiofilm activity was maintained for 7 days with reduction values up to 4 log (reduction of biofilm superior to 99.99%). The application of the neutral dressing also induced a significant reduction of the concentration of sessile cells after 1 day (about 0.90 log). The results obtained with this neutral form of the dressing showed that the polyacrylate fibres were able to exert a mechanical disruption of the biofilm architecture.


CONCLUSIONS
These in vitro experiments demonstrated that silver polyabsorbent dressing was able to strongly reduce the biofilm of MRSA. The antibiofilm mechanism of this dressing can be explained by a dual action of the polyabsorbent fibres (based on ammonium polyacrylate polymer around an acrylic core) which induced a mechanical disruption of the biofilm matrix and/or a sequestration of sessile cells, and the diffusion of silver ions which produced bactericidal activity.


BACKGROUND
This study was supported by Laboratoires Urgo (Dijon). P. Janod is an employee of Laboratoires Urgo. The company had no influence on the experimental design and the interpretation of the results.
Nexidia SAS, 15 Rue de Mayence, F-21000 DIJON.
N
N
Desroche
Nexidia SAS, 15 Rue de Mayence, F-21000 DIJON.
C
C
Dropet
Urgo Recherche Innovation et Développement, 42 rue de Longvic, F-21300 CHENOVE.
P
P
Janod
UMR A, Procédés Alimentaires et Microbiologiques, Université de Bourgogne, IUVV, rue Claude Ladrey, F-21000 DIJON.
J
J
Guzzo
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001458:Bandages / Q000382:microbiology*; D018441:Biofilms / Q000187:drug effects*; D006801:Humans; D020100:Hydrogels / Q000494:pharmacology / Q000627:therapeutic use*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D018030:Silver Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D014945:Wound Healing; D014946:Wound Infection / Q000188:drug therapy* / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D020100:Hydrogels; C500575:SilvaSorb; D018030:Silver Compounds
MRSA; antibacterial activity; biofilm; mechanical effect; polyacrylate fibres; silver-containing wound dressing